vs
必能宝（PBI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是必能宝的1.6倍（$772.1M vs $477.6M），Revvity净利率更高（12.7% vs 5.7%，领先7.0%），Revvity同比增速更快（5.9% vs -7.5%），必能宝自由现金流更多（$201.4M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -4.3%）
必能宝（Pitney Bowes）是全球知名科技与物流服务商，提供电商配送、邮寄处理、订单履约及客户信息管理解决方案，服务零售、金融、医疗、政府等领域的各类大中小企业客户，助力企业优化物流配送与客户运营效率。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PBI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$477.6M
营收增速更快
RVTY
高出13.3%
-7.5%
净利率更高
RVTY
高出7.0%
5.7%
自由现金流更多
PBI
多$39.7M
$161.8M
两年增速更快
RVTY
近两年复合增速
-4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $477.6M | $772.1M |
| 净利润 | $27.3M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 14.5% |
| 净利率 | 5.7% | 12.7% |
| 营收同比 | -7.5% | 5.9% |
| 净利润同比 | 173.1% | 3.9% |
| 每股收益（稀释后） | $0.18 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBIRVTY
| Q4 25 | $477.6M | $772.1M | ||
| Q3 25 | $459.7M | $698.9M | ||
| Q2 25 | $461.9M | $720.3M | ||
| Q1 25 | $493.4M | $664.8M | ||
| Q4 24 | $516.1M | $729.4M | ||
| Q3 24 | $499.5M | $684.0M | ||
| Q2 24 | $489.7M | $691.7M | ||
| Q1 24 | $521.3M | $649.9M |
净利润PBIRVTY
| Q4 25 | $27.3M | $98.4M | ||
| Q3 25 | $52.0M | $46.7M | ||
| Q2 25 | $30.0M | $53.9M | ||
| Q1 25 | $35.4M | $42.2M | ||
| Q4 24 | $-37.4M | $94.6M | ||
| Q3 24 | $-138.5M | $94.4M | ||
| Q2 24 | $-24.9M | $55.4M | ||
| Q1 24 | $-2.9M | $26.0M |
毛利率PBIRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 53.8% | — | ||
| Q3 24 | 52.4% | 56.3% | ||
| Q2 24 | 51.1% | 55.7% | ||
| Q1 24 | 52.3% | 54.6% |
营业利润率PBIRVTY
| Q4 25 | 8.0% | 14.5% | ||
| Q3 25 | 14.8% | 11.7% | ||
| Q2 25 | 8.5% | 12.6% | ||
| Q1 25 | 9.5% | 10.9% | ||
| Q4 24 | -9.3% | 16.3% | ||
| Q3 24 | -8.8% | 14.3% | ||
| Q2 24 | -1.6% | 12.4% | ||
| Q1 24 | 9.1% | 6.8% |
净利率PBIRVTY
| Q4 25 | 5.7% | 12.7% | ||
| Q3 25 | 11.3% | 6.7% | ||
| Q2 25 | 6.5% | 7.5% | ||
| Q1 25 | 7.2% | 6.4% | ||
| Q4 24 | -7.2% | 13.0% | ||
| Q3 24 | -27.7% | 13.8% | ||
| Q2 24 | -5.1% | 8.0% | ||
| Q1 24 | -0.6% | 4.0% |
每股收益（稀释后）PBIRVTY
| Q4 25 | $0.18 | $0.86 | ||
| Q3 25 | $0.30 | $0.40 | ||
| Q2 25 | $0.17 | $0.46 | ||
| Q1 25 | $0.19 | $0.35 | ||
| Q4 24 | $-0.21 | $0.77 | ||
| Q3 24 | $-0.75 | $0.77 | ||
| Q2 24 | $-0.14 | $0.45 | ||
| Q1 24 | $-0.02 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $297.1M | $919.9M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $-802.4M | $7.3B |
| 总资产 | $3.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PBIRVTY
| Q4 25 | $297.1M | $919.9M | ||
| Q3 25 | $336.0M | $931.4M | ||
| Q2 25 | $300.8M | $991.8M | ||
| Q1 25 | $340.0M | $1.1B | ||
| Q4 24 | $486.1M | $1.2B | ||
| Q3 24 | $575.5M | $1.2B | ||
| Q2 24 | $612.0M | $2.0B | ||
| Q1 24 | $538.0M | $1.7B |
总债务PBIRVTY
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
股东权益PBIRVTY
| Q4 25 | $-802.4M | $7.3B | ||
| Q3 25 | $-661.5M | $7.4B | ||
| Q2 25 | $-536.8M | $7.6B | ||
| Q1 25 | $-535.9M | $7.6B | ||
| Q4 24 | $-578.4M | $7.7B | ||
| Q3 24 | $-518.9M | $7.9B | ||
| Q2 24 | $-427.9M | $7.9B | ||
| Q1 24 | $-392.4M | $7.8B |
总资产PBIRVTY
| Q4 25 | $3.2B | $12.2B | ||
| Q3 25 | $3.3B | $12.1B | ||
| Q2 25 | $3.2B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.6B | $12.8B | ||
| Q2 24 | $4.1B | $13.4B | ||
| Q1 24 | $4.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $221.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $201.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 42.2% | 21.0% |
| 资本支出强度资本支出/营收 | 4.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 8.11× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $317.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PBIRVTY
| Q4 25 | $221.7M | $182.0M | ||
| Q3 25 | $66.8M | $138.5M | ||
| Q2 25 | $111.4M | $134.3M | ||
| Q1 25 | $-16.7M | $128.2M | ||
| Q4 24 | $134.5M | $174.2M | ||
| Q3 24 | $14.7M | $147.9M | ||
| Q2 24 | $92.6M | $158.6M | ||
| Q1 24 | $-12.6M | $147.6M |
自由现金流PBIRVTY
| Q4 25 | $201.4M | $161.8M | ||
| Q3 25 | $51.1M | $120.0M | ||
| Q2 25 | $98.0M | $115.5M | ||
| Q1 25 | $-33.6M | $112.2M | ||
| Q4 24 | $112.3M | $149.8M | ||
| Q3 24 | $-4.7M | $125.6M | ||
| Q2 24 | $76.1M | $136.6M | ||
| Q1 24 | $-26.9M | $129.7M |
自由现金流率PBIRVTY
| Q4 25 | 42.2% | 21.0% | ||
| Q3 25 | 11.1% | 17.2% | ||
| Q2 25 | 21.2% | 16.0% | ||
| Q1 25 | -6.8% | 16.9% | ||
| Q4 24 | 21.8% | 20.5% | ||
| Q3 24 | -0.9% | 18.4% | ||
| Q2 24 | 15.5% | 19.7% | ||
| Q1 24 | -5.2% | 20.0% |
资本支出强度PBIRVTY
| Q4 25 | 4.2% | 2.6% | ||
| Q3 25 | 3.4% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 3.4% | 2.4% | ||
| Q4 24 | 4.3% | 3.4% | ||
| Q3 24 | 3.9% | 3.3% | ||
| Q2 24 | 3.4% | 3.2% | ||
| Q1 24 | 2.7% | 2.7% |
现金转化率PBIRVTY
| Q4 25 | 8.11× | 1.85× | ||
| Q3 25 | 1.29× | 2.97× | ||
| Q2 25 | 3.72× | 2.49× | ||
| Q1 25 | -0.47× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBI
| Sales And Services | $218.4M | 46% |
| Presort Services | $159.7M | 33% |
| Financing And Other | $79.0M | 17% |
| Other | $20.5M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
